타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Disitamab Vedotin (RC48) |
Overview Company | RemeGen |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | HER2+ urothelial, gastric, breast |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Positioning Key differentiator | Novel anti-HER2 mAb with distinct epitope |
Positioning Known limitation | resistance mechanisms, optimize payload delivery, and minimize off-target toxicity |
Positioning Development positioning | 2L+ |
Technology Payload | MMAE |
Technology Linker | Cleavable |
MoA Mechanism | Disitamab vedotin binds a distinct HER2 epitope (different from trastuzumab), internalizes, and releases MMAE via cleavable linker, causing microtubule disruption and apoptosis. |
MoA Biomarker | HER2 expression (IHC); activity in HER2+ urothelial and gastric cancers. |
Toxicology Species | Cynomolgus monkey |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. |
Toxicology CRS | N/A |
Clinical Safety signal | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Disitamab Vedotin (RC48) |
Overview Company | RemeGen |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | HER2+ urothelial, gastric, breast |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Positioning Key differentiator | Novel anti-HER2 mAb with distinct epitope |
Positioning Known limitation | resistance mechanisms, optimize payload delivery, and minimize off-target toxicity |
Positioning Development positioning | 2L+ |
Technology Payload | MMAE |
Technology Linker | Cleavable |
MoA Mechanism | Disitamab vedotin binds a distinct HER2 epitope (different from trastuzumab), internalizes, and releases MMAE via cleavable linker, causing microtubule disruption and apoptosis. |
MoA Biomarker | HER2 expression (IHC); activity in HER2+ urothelial and gastric cancers. |
Toxicology Species | Cynomolgus monkey |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. |
Toxicology CRS | N/A |
Clinical Safety signal | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교